DHODH-IN-26 (compound B2) is a mitochondrial DHODH inhibitor with anticancer properties. It induces the generation of reactive oxygen species (ROS), promotes mitochondrial lipid peroxidation, and triggers ferroptosis.

DHODH-IN-26 (compound B2) inhibits the growth of 4T1, B16F10, U251, GL261, SH-SY5Y, U87, and A375 cells at concentrations ranging from 0.01 to 100 μM over 72 hours. Additionally, DHODH-IN-26 at 50 and 100 nM suppresses colony formation in B16F10 and A375 cells, and reduces PD-L1 protein expression in these cells over 48 hours.

Compound B2 (DHODH-IN-26), administered via intraperitoneal injection at a dose of 50 mg/kg for a duration of 14 consecutive days, effectively inhibits tumor growth in a B16F10 xenograft model using C57BL/6 mice.